Uterine Cervical Dysplasia clinical trials
The registry lists 409 studies for Uterine Cervical Dysplasia across more than 10 countries. 76 are recruiting or about to start. 244 of them are mainly about Uterine Cervical Dysplasia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Atypical Squamous Cells of the Cervix: 426 studies, 80 open.
Get an email when these change. Save the Uterine Cervical Dysplasia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
M.D. Anderson Cancer Center (14) · National Cancer Institute (NCI) (12) · GlaxoSmithKline (10) · Zydolab - Institute of Cytology and Immune Cytochemistry (9) · University of Aarhus (9) · British Columbia Cancer Agency (8) · Ruhr University of Bochum (7) · Barretos Cancer Hospital (6)
What is being tested here
Drugs under test in Uterine Cervical Dysplasia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Antimetabolites 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Dec 2026Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 · Shanghai Zerun Biotechnology Co.,Ltd
- Dec 2026Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance. · University of Aarhus
- Dec 2026A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. · Papillex Inc.
- Dec 2026Self-sampling for Non-attenders to Cervical Cancer Screening · The Institute of Molecular and Translational Medicine, Czech Republic
- Dec 2026Effect of Honey For CIN II · Zuyderland Medisch Centrum
- Dec 2026Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities · Amplexd Therapeutics, Inc.
- Dec 2026Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma · Lindsay Ferguson, MD
- Dec 2026Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls · Xiamen University
- Dec 2026PRIORITY Study in Cervical Cancer · Pontificia Universidad Catolica de Chile
- Jan 2027VIA Versus Colposcopy · Sohag University
Who these studies take
Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger. 3 (7%) take children under 18. 40 (93%) are for women only and 0 (0%) for men only; 11 (26%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (7%) | 0 (0%) |
| 18 | 24 (56%) | 3 (7%) |
| 30 | 41 (95%) | 3 (7%) |
| 40 | 42 (98%) | 3 (7%) |
| 50 | 32 (74%) | 3 (7%) |
| 65 | 26 (60%) | 3 (7%) |
| 75 | 22 (51%) | 2 (5%) |
| 85 | 22 (51%) | 2 (5%) |
Across all 409 studies, recruiting or not: 50% stop at 75 or younger and 45% at 65; 10% take children; 96% are for women only and 0% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Uterine Cervical Dysplasia studies take
Of 20 phase 2 interventional studies under Uterine Cervical Dysplasia, half reached primary completion within 38 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 17 mo10–67 · 14 studies | — | — |
| Phase 2 | 38 mo17–70 · 20 studies | — | — |
| Interventional, no phase | 26 mo13–54 · 82 studies | — | 24 mo13–54 · 78 studies |
| Observational | 61 mo30–… · 44 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting6
- C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNov 12, 2026NCT07576842
- The Mother-Daughter Project: Merck-4Nov 10, 2026NCT07240220
- Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 KenyaOct 20, 2026NCT07468695
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South AfricaOct 20, 2026NCT07645378
- Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 RwandaOct 19, 2026NCT07390916
Show 1 moreShow fewer
Newly registered5
- High-risk HPV Testing With Pap Smear Triage for Cervical Cancer Screening in Women Aged 50 and Older in EthiopiaNov 10, 2026NCT07929246
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNov 9, 2026NCT07925307
- Clinical Audit of Cervical Cytology Services in an Early Cancer Detection UnitOct 27, 2026NCT07897786
- Predictive Biomarkers for Precision Management of Pre-cancerous Cervical NeoplasiaOct 26, 2026NCT07895641
- Exploratory Study of the Efficacy of HAL-PDT in CIN 3Oct 23, 2026NCT07891338
Studies
Recruiting first, then most recently updated. Showing 50 of 409. Browse all 409 → or search them.
- C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVRecruitingNCT07576842Not applicable1 country
- High-risk HPV Testing With Pap Smear Triage for Cervical Cancer Screening in Women Aged 50 and Older in EthiopiaNot yet recruitingNCT07929246
- The Mother-Daughter Project: Merck-4RecruitingNCT07240220Not applicable1 country
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVRecruitingNCT07925307Not applicable1 country
- Role of Liquid Biopsies in HPV-associated Cancer Treatment MonitoringRecruitingNCT057745611 country
- Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical CancerRecruitingNCT050517221 country
- Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 RwandaRecruitingNCT07390916Not applicable1 country
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS7 ZimbabweRecruitingNCT07645352Not applicable1 country
- Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South AfricaRecruitingNCT07645378Not applicable1 country
- Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 KenyaRecruitingNCT07468695Not applicable1 country
- Clinical Audit of Cervical Cytology Services in an Early Cancer Detection UnitNot yet recruitingNCT07897786
- Exploratory Study of the Efficacy of HAL-PDT in CIN 3Not yet recruitingNCT07891338Phase 21 country
- RWS of PDT for CIN 2Not yet recruitingNCT07885566
- C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United StatesNot yet recruitingNCT075201881 country
- Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology StudiesEnrolling by invitationNCT042660931 country
- Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active SurveillanceRecruitingNCT07730645Not applicable1 country
- Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005Enrolling by invitationNCT078338521 country
- Phase I/II Trial of Electroporation-Delivered pBI-4 Vaccine (TriGrid™ PVX4) for Treatment of Women With HPV16-Positive CIN1 or Persistent InfectionNot yet recruitingNCT07809997Phase 1/21 country
- Local Hyperthermia for the Treatment of Cervical Persistent High-risk InfectionEnrolling by invitationNCT07059819Not applicable1 country
- Point of Care - Triage and Treatment for Cervical Pre-cancerRecruitingNCT07461818Not applicable1 country
- Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in KenyaNot yet recruitingNCT07545746Phase 21 country
- Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance.RecruitingNCT07429071Not applicable1 country
- Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical CarcinomaRecruitingNCT06191133Phase 11 country
- VIA Versus ColposcopyNot yet recruitingNCT07692919
- Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)Not yet recruitingNCT07669363Phase 21 country
- A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.RecruitingNCT06979180Not applicable1 country
- HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical NeoplasiaRecruitingNCT04131413Phase 11 country
- HAL-PDT for Cervical Intraepithelial Neoplasia Grade 2Not yet recruitingNCT07634497
- Peripheral Blood CyTOF Immune Model for Cervical Lesion Detection in HPV16/18+ WomenNot yet recruitingNCT07606677
- PRIORITY Study in Cervical CancerNot yet recruitingNCT075930661 country
- Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic AbnormalitiesRecruitingNCT07572396Phase 21 country
- PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical DysplasiaRecruitingNCT07454915Phase 22 countries
- Self-sampling for Non-attenders to Cervical Cancer ScreeningRecruitingNCT04226313Not applicable1 country
- Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical CancerRecruitingNCT07480902Not applicable1 country
- HIFU vs Observation for LSIL of Cervix: A Randomized Controlled TrialNot yet recruitingNCT07461064Not applicable
- Thermal Artifact in Patients Undergoing Conization: A Clinical StudyRecruitingNCT07372248Not applicable1 country
- MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)Not yet recruitingNCT07379905Not applicable
- The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer PatientsNot yet recruitingNCT073859761 country
- Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical CancerRecruitingNCT06815939Not applicable1 country
- Human Papillomavirus Self-sampling for Enhancing Cervical Screening During the War in UkraineRecruitingNCT07275333Not applicable1 country
- Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)RecruitingNCT04098744Phase 21 country
- Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic CancersRecruitingNCT05606133Not applicable1 country
- Primary HPV Self-Collection in IndonesiaEnrolling by invitationNCT06942286Not applicable1 country
- Empowering Women - Shared Decision Making in Managing Cervical PrecancerNot yet recruitingNCT07146152Not applicable1 country
- Epidemiological Factors and Optimization of Conservative Approaches to Precancerous Lesions of Female Reproductive OrgansRecruitingNCT069677401 country
- Effect of Honey For CIN IIRecruitingNCT06219018Phase 1/21 country
- Evaluation of the PreCursor-M+® in CIN2RecruitingNCT064036181 country
- Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.RecruitingNCT03061435Not applicable1 country
- Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIVRecruitingNCT05266898Phase 41 country
- The Organ Transplant Recipient HPV and Skin Cancer StudyRecruitingNCT052848771 country